CSIMarket
 
Bionexus Gene Lab Corp   (BGLC)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.5464 $0.01 0.998%
Day's High: $0.575 Week Perf: -4.14 %
Day's Low: $ 0.54 30 Day Perf: -6.12 %
Volume (M): 89 52 Wk High: $ 3.39
Volume (M$): $ 49 52 Wk Avg: $0.70
Open: $0.56 52 Wk Low: $0.31



 Market Capitalization (Millions $) 10
 Shares Outstanding (Millions) 18
 Employees -
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0

Bionexus Gene Lab Corp
Bionexus Gene Lab Corp is a biotechnology company that focuses on genetic research and development. The company specializes in genetic testing, analysis, and sequencing for various applications such as personalized medicine, drug discovery, and agricultural biotechnology. The lab utilizes advanced technologies and techniques to understand genetic variations and their impact on human health and the environment. Bionexus Gene Lab Corp aims to provide valuable insights and innovative solutions through its genetic research to improve health outcomes and promote sustainable practices.


   Company Address: Unit 02, Level 10 Tower B, Avenue 3, The Vertical Kuala Lumpur 59200
   Company Phone Number: 241 6898   Stock Exchange / Ticker: NASDAQ BGLC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Bionexus Gene Lab Corp

Financial Results Show Mixed Performance for Bionexus Gene Lab Corp in Q1 20242.

Bionexus Gene Lab Corp (BGLC) recently released its financial results for the fiscal period ending March 31, 2024, painting a mixed picture of the company's performance. While revenue saw a modest increase compared to the previous year, deficits per share grew and income per share declined. This trend, coupled with a larger net deficit realized by the company, has raised concerns among investors and analysts.
Specifically, BGLC reported a deficit per share of $-0.02 for the period, a significant increase from the $0.00 per share reported a year prior. Additionally, income per share fell from $0.02 to an undisclosed amount, indicating a decrease in profitability for the company. Despite a 0.195% increase in revenue to $2.38 million, the growth rate lags behind that of its peers in the Medical Laboratories sector.

Management Announcement

Zefiro Methane CEO Talal Debs Unveils Innovative Approach to Tackle Methane Emissions, Reflecting on Early Carbon Market Experiences

Published Fri, Apr 19 2024 2:00 PM UTC



In a recent episode of the Smarter Markets podcast, Talal Debs, the Founder and CEO of Zefiro Methane, shed light on his early experiences in the carbon markets, providing valuable insights into the genesis of Zefiro and its groundbreaking methodology in addressing the pressing issue of methane emissions.
During the 36-minute interview, Dr. Debs shared his firs...

Announcement

BioNexus Gene Lab Corp. Announces RM 1.2 Million Investment in AISB to Boost AI Adoption and Revolutionize Healthcare

Published Thu, Apr 18 2024 6:53 PM UTC

In a ground-breaking alignment, BioNexus Gene Lab Corp., a renowned global biotechnological, genomic research, and gene testing organization, has pledged to infuse RM 1.2 million into Ascension Innovation, a leading digital health solutions provider. This collaborative endeavor aims to accelerate digital healthcare innovation and, importantly, streamline the integration and ...

Bionexus Gene Lab Corp

Bionexus Gene Lab Corp Reports Modest Growth in Top-line Revenue during Fiscal Q2 2023



Bionexus Gene Lab Corp (BGLC) recently released its financial results for the second quarter of 2023. In order to understand the implications of these results and their potential effects on the company's future, it is crucial to delve deeper into the figures and analyze them in the context of the overall medical laboratories sector.
Revenue Growth and Comparison:
During the second quarter of 2023, BGLC's revenue witnessed a slight increase of 3.289% to reach $2.57 million. This should be seen in relation to the corresponding period a year earlier, when the company generated $2.49 million in revenue. Furthermore, Q2 2023 revenue also recorded a sequential growth of 7.978% from $2.38 million.






 

Bionexus Gene Lab's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Bionexus Gene Lab does not provide revenue guidance.

Earnings Outlook
Bionexus Gene Lab Corp does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com